AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Intro
The chapter delves into the FDA's fast track approval of Amgen's lung cancer therapy, Sotoresab, and the implications of a study comparing high and low doses, revealing minimal efficacy gains with higher dosage but increased side effects, leading to safety and financial concerns.